Bladder Cancer Treatment Protocols

ARTICLES

Bladder Cancer Treatment Protocols

MEDSCAPE

PUBLISHED: 04 MAY 2020

Second-line chemotherapy for muscle invasive bladder cancer: Erdafitinib 8 mg PO qd initially; increase to 9 mg PO qd based on serum phosphate levels and tolerability at 14-21 days; for metastatic urothelial carcinoma that has FGFR2 or FGFR3 genetic alterations and that progressed during or following at least 1 line of prior platinum-containing chemotherapy